Immunological Evaluation of a Novel Mycobacterium tuberculosis Antigen Rv0674.

Tong Yang Xiao; Hai Can Liu; Xiao Qin LI; Ming Xiang Huang; Gui Lian LI; Na LI; Yu Han Yan; Qiao Luo; Xue Zhi Wang; Ma Chao LI; Kang Lin Wan

Return

Immunological Evaluation of a Novel Mycobacterium tuberculosis Antigen Rv0674.

Author: Tong Yang XIAO ¹ ; Hai Can LIU ¹ ; Xiao Qin LI ^{2
,

3} ; Ming Xiang HUANG ⁴ ; Gui Lian LI ¹ ; Na LI ¹ ; Yu Han YAN ^{2
,

3} ; Qiao LUO ⁵ ; Xue Zhi WANG ⁶ ; Ma Chao LI ¹ ; Kang Lin WAN ¹
Author Information

1. State Key Laboratory for Infectious Diseases Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
2. State Key Laboratory for Infectious Diseases Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
3. Key Laboratory of Laboratory Medicine, Ministry of Education, College of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou 325035, Zhejiang, China.
4. Clinical laboratory, Fuzhou Pulmonary Hospital, Fuzhou 350008, Fujian, China.
5. The first hospital of Changsha, Changsha 410005, Hunan, China.
6. Key laboratory of Translational Medicine of Guangdong, Center for Tuberculosis Control of Guangdong Province, Guangzhou 510630, Guangdong, China.
Publication Type:Journal Article
Keywords: Antigen; Immunologic diagnosis; Mycobacterium tuberculosis; Rv0674; Vaccine
MeSH: Adult; Aged; Animals; Antigens, Bacterial; immunology; Female; Humans; Immunity, Cellular; Immunity, Humoral; Male; Mice; Mice, Inbred BALB C; Middle Aged; Tuberculosis; diagnosis; immunology; Young Adult
From: Biomedical and Environmental Sciences 2019;32(6):427-437
CountryChina
Language:English
Abstract: OBJECTIVE:This study aimed to characterize the diagnostic and vaccine potential of a novel Mycobacterium tuberculosis antigen Rv0674.
METHODS:To evaluate the diagnostic potential and antigenicity of Rv0674, IgG was evaluated using ELISA and interferon (IFN)-γ was done by using ELISpot assay among TB patients and healthy donors. For immunogenicity evaluation, BALB/c mice were immunized with Rv0674. Cytokine production was determined by cytokine release assay using an ELISA kit, and the antibodies were tested using ELISA.
RESULTS:The results of serum Elisa tests showed that Rv0674 specific immunoglobulin G (IgG) response was higher in TB patients than negative controls. And Rv0674 had good performance in serological test with sensitivity and specificity of 77.1% and 81.1%, respectively. While it shows poor sensitivity and specificity of 26.23% and 79.69% for IFN-γ tests. In BALB/c mice, Rv0674 adjuvant by DDA/Poly I:C could also induce a high level of IFN-γ, interleukin-2 and interleukin-6 as well as a high IgG titer in both high- and low-dose groups indicating that Rv0674 is essential in humoral and cellular immunity. Moreover, the cytokine profile and IgG isotype characterized Rv0674 as a Th1/Th2-mixed-type protective immunity with the predominance of Th1 cytokines.
CONCLUSION:Rv0674 may be a good potential candidate for the development of TB serological diagnosis and a new TB vaccine.